Journal of nanobiotechnology · 2026
Empagliflozin-pretreated mesenchymal stem cell-derived extracellular vesicles facilitate cardiac repair via AGGF1.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Qianwen, Gu Qingqing, Wei Jun, Deng Li, Deng Ye, Wang Jingyi, Huang Jianya, Sun Tingting, Pan Lu, Mao Wenjun, Wang Qingjie, Wang Ruxing, Sun Ling
Аннотация
BACKGROUND: Current treatment modalities can only reap a limited efficacy in reversing myocardial damage and promoting functional recovery in patients with myocardial infarction. Therefore, there is an urgent need to explore new therapeutic approaches to enhance cardiac repair.
METHODS: MSCs were pretreated with empagliflozin to obtain EMPA-EVs, with non-pretreated MSC-EVs serving as controls. In vitro experiments were conducted to evaluate the effects of the two types of EVs on macrophage phenotypic transformation, cardiomyocyte apoptosis, and vascular endothelial cell lumen formation. In vivo experiments, a rat model of myocardial infarction was constructed, and EMPA-EVs, non-pretreated MSC-EVs, or phosphate-buffered saline were administered via myocardial injection. Post-treatment assessments included left ventricular ejection fraction, myocardial infarction area, and levels of pro-inflammatory cytokines in myocardial tissue. In addition, AGGF1 was depleted in EMPA-EVs to observe their anti-apoptotic, anti-inflammatory, and pro-angiogenic effects.
RESULTS: Compared with non-pretreated MSC-EVs, EMPA-EVs increased the proportion of macrophages transforming into anti-inflammatory phenotypes, decreased the rate of apoptotic cardiomyocytes, and promoted the formation of vascular endothelial cell lumen. Animal experiments showed that the left ventricular ejection fraction of rats in the EMPA-EVs group was higher than that in the control group, the myocardial infarction area was reduced, and the level of pro-inflammatory factors in myocardial tissue decreased. Moreover, AGGF1 expression was significantly upregulated in EMPA-EVs, and the anti-apoptotic, anti-inflammatory, and pro-angiogenic effects of EMPA-EVs were inhibited upon AGGF1 knockdown.
CONCLUSION: EMPA-EVs can promote cardiac repair in myocardial infarction, and this therapeutic effect involves the upregulation of AGGF1 and may promise a cell-free therapeutic strategy.
METHODS: MSCs were pretreated with empagliflozin to obtain EMPA-EVs, with non-pretreated MSC-EVs serving as controls. In vitro experiments were conducted to evaluate the effects of the two types of EVs on macrophage phenotypic transformation, cardiomyocyte apoptosis, and vascular endothelial cell lumen formation. In vivo experiments, a rat model of myocardial infarction was constructed, and EMPA-EVs, non-pretreated MSC-EVs, or phosphate-buffered saline were administered via myocardial injection. Post-treatment assessments included left ventricular ejection fraction, myocardial infarction area, and levels of pro-inflammatory cytokines in myocardial tissue. In addition, AGGF1 was depleted in EMPA-EVs to observe their anti-apoptotic, anti-inflammatory, and pro-angiogenic effects.
RESULTS: Compared with non-pretreated MSC-EVs, EMPA-EVs increased the proportion of macrophages transforming into anti-inflammatory phenotypes, decreased the rate of apoptotic cardiomyocytes, and promoted the formation of vascular endothelial cell lumen. Animal experiments showed that the left ventricular ejection fraction of rats in the EMPA-EVs group was higher than that in the control group, the myocardial infarction area was reduced, and the level of pro-inflammatory factors in myocardial tissue decreased. Moreover, AGGF1 expression was significantly upregulated in EMPA-EVs, and the anti-apoptotic, anti-inflammatory, and pro-angiogenic effects of EMPA-EVs were inhibited upon AGGF1 knockdown.
CONCLUSION: EMPA-EVs can promote cardiac repair in myocardial infarction, and this therapeutic effect involves the upregulation of AGGF1 and may promise a cell-free therapeutic strategy.